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1. Introduction
In past times behavioural neurologists have shown how discrete brain lesions provoked
different types of cognitive disorders such as language, praxic, gnostic, spatial or memory
domain.
They interpreted these anatomo-clinical associations conjecturing that the normal brain
function (impaired by brain damage) was localized within the lesioned region (lesional
hypothesis) and had been impaired from brain damage (Marshall & Fink, 2003). They also
hypothesized that cognitive impairments could arise from lesions that spared the functional
centers but disconnected them from other centers (disconnectional hypothesis). According this
argument “basic psychological functions” are localized in a punctate fashion and complex
psychological functions are constituted from many such basic functions joined together in
distributed circuits. It follows that the symptoms may have arisen from a reconfiguration of
the entire circuit in response to cerebral damage.
During the late 19th century, the advent of structural brain imaging, first the computed
tomography (CT) and later the magnetic resonance imaging (MRI), gave the possibility to
study anatomical localization of the cognitive deficits that were manifest after brain injury.
Since then neuroimaging studies have helped medical doctors in clinical practice to identify
cerebral damage caused by spaced-occupying lesions, strokes or degenerative processes.
During the 20th century other instrumental techniques such as single photon computed
tomography (SPECT), positron emission tomography (PET), functional magnetic resonance
imaging (f-MRI) or magnetoencephalography (MEG) started to be used for evaluation of
cognitive activation not only in patients with cerebral lesions, but also in living normal brains
and localize mental faculties in different regions of the brain. Further, functional techniques
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and both can be thought as originating from imaging and functional technologies: neuroelec‐
trical (MEG and electroencephalography), and hemodynamic (PET, SPECT, fMRI, optical).
These advances in medical technology have led to study structural brain imaging early in
patients, explore relationship between structure and function or hypothesize brain cognitive
functioning also in normal subjects.
For example Positron Emission Tomography has been used in healthy volunteers to study
brain activation during specific goal-directed behaviours (Raichle et al., 2001) such as arith‐
metical computation (Dehaene et al., 1996), memory tasks, visuoconstructive abilities or
specific language tasks.
Since then various neuroimaging technologies have also been applied to identify and measure
a range of biological processes that occur along neurological disease associated with cognitive
impairment as in neurodegenerative conditions.
In this chapter we will review some applications of PET in understanding the cognitive
functions in normal subjects, in patients with cognitive deficits during normal aging or
following vascular or degenerative damage.
We will also discuss how PET scanning of glucose metabolism, could be used to differentiate
Alzheimer’s disease from other forms of dementia such as Vascular dementia, Lewy boby
dementia or Frontotemporal dementia, which helps to guide clinicians in symptomatic
treatment strategies.
We will also expose how PET exam could be useful to identify potential risk of developing
dementia in persons with mild cognitive impairment (MCI) resulting useful in predicting
further cognitive decline.
2. Pet study of human cognitive functions
The human brain is an extremely complex organ. The energy required for this complex
structure is almost exclusively covered by oxidative metabolism of glucose (Clarke and
Sokoloff, 1999). Since PET is a technology based on study of glucose metabolism has great
impact on research in study of human cerebral activity.
PET has been adopted in normal subject to study cognitive functions in a particular case of
functional connectivity that is the so-called default mode or “resting state connectivity”,
successively extended with fMRI studies. It quantified the spatial correlation of brain activity
in the absence of a specific cognitive task. Typically, this is performed by having the subject
fixate a visual cue in the absence of a cognitive task (Raichle and Mintun, 2006). The baseline
activity of the resting state has spatial correlations that involve the same prefrontal, medial
temporal lobe and parietal lobe systems involved in some memory tasks. It could be hypothe‐
sized that memory system, especially the declarative memory system, might be activated in
the resting state (Vincent et al., 2006).
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“Functional effective connectivity” consists in the measure of correlation of connectivity
among brain regions or better the influence of brain nodes on each other. PET studies have
been applied to quantify causal interactions between brain regions (McIntosh et al., 1994;
Horwitz et al., 2005). This measure estimates the strength of connectivity between cerebral
areas and statistically infers a causal effect of connectivity. For example a PET study of human
working memory for faces has suggested that the network for underlying activity changes as
the task requirements change (McIntosh et al., 1996). Models of connectivity have been
explored with PET in the study dynamic neural networks underlying language processing
using specific tasks such as word generation (Warburton et al., 1996) or reading (Price and
Friston, 1997). PET studies have also been applied to demonstrate hemispheric dominance of
language. The laterality of language is usually achieved by activating language areas and
comparing the relative strength of activation between the right and the left hemispheres
(Stippich et al., 2003; Lohmann et al., 2004). Studies on multiple groups have reported a strong
correlation with PET or fMRI compared with intraoperative mapping techniques and the
results of classical Wada test (Roux et al., 2003; Woermann et al., 2003; Atlas et al., 1996).
PET or task-activated fMRI can locate, with a high spatial resolution, both receptive and
productive language areas. One practical application of PET for language localization consists
in the presurgical evaluation of epileptic or brain tumor patients. This PET neurosurgical
application makes possible a precise localization of essential language areas in individual
patient rather then participating areas. Essential language areas are ones that when removed
result in a language deficit; while participating areas are ones that are activated during
language paradigms, but do not result in a post-operative language deficit after surgical
resection, because these are areas of redundant processing or because other areas learn to take
over the same function. Currently, there is no way to distinguish essential from participating
areas with non-invasive imaging and improving the detection of essential areas is a major goal
of clinical functional imaging. Language areas found to be lateralized in left hemisphere with
a variety of language tasks are essentials four: prefrontal cortex (inferior frontal gyrus, superior
frontal gyrus and the anterior cingulate), angular gyrus (excluding the supramarginal gyrus),
ventrolateral temporal lobe (superior temporal, middle temporal, inferior temporal and
fusiform gyri) and retrosplenial cortex. This means that studies on patients with lesion of
anterior lateral prefrontal cortex (known as Broca’s area) overemphasize the role of these
cerebral areas in onset of language disorder (Broca’s aphasia) as confirmed by patients with
isolated lesions of “Broca’s areas” having only apraxis deficits of articulation rather then
aphasia. On the other hands a real and permanent Broca’s aphasia requires more extensive
cerebral lesions involving anterior frontal gyrus, middle frontal gyrus and peri-central gyri.
These functional studies suggest that a wide area of left frontal lobe participate in language
processing outside the classical confines of Broca’s area, as confirmed by clinical cases of people
with large frontal stroke and receptive aphasia which later may evolve into a so-called
expressive aphasia. Task activated fMRI provide evidence of cortical reorganization of
language areas, do to tumoral lesions or after a surgical resection.
PET, fMRI, MEG and EEG have been used in numerous studies to investigate the cerebral
sites of declarative memory (for a review see Gazzaniga, 2004) that consists in explicit memory
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for facts and events. Declarative memory has often been studied using the so-called “subse‐
quent memory effect” that is brain activity during encoding of items that are subsequently
forgotten. On the other way the retrieval of declarative memory has been studied with the
“old/new effect” that consists is the comparison of brain activity recorded during correctly
recognized old items versus correctly identified new items. Memory for events involves
processing in the medial temporal lobes (Milner et al., 1998) and in the prefrontal cortex. Frontal
lobe activity is related to both encoding and retrieval of memory events for both long-term
and short-term memory.
Functional memory localization has been applied in presurgical evaluation of epileptic (Detre,
2004) or brain tumor patients and predicts post-surgical memory deficits following temporal
lobectomy (Rabin et al., 2004).
Episodic (conscious memory of events) and semantic memory (memory concerned with ideas,
meanings, and concepts which are not related to personal experiences) might recruit different
brain areas (Tulving and Markowitsch, 1998). In fact, amnesic patients with specific episodic
memory impairment (intact priming, category learning, learning of artificial grammars) have
temporal lobe damage, while patients with semantic deficits show dysfunction in prefrontal
cortex. In particular left prefrontal cortex increases activity during semantic encoding while
right prefrontal cortex increases activity during retrieval task. Recent neuroimaging studies
implicate also the parietal lobe in episodic memory (Wagner et al., 2005).
Functional studies on working memory (memory that makes possible the temporary retention
of information) suggest an overlapping of brain mechanism with attention (Jha, 2002) and
associative learning in prefrontal cortex (Fuster et al., 2000). This association has also been
demonstrated on behavioural studies (Sheth and Shimojo, 2003). Many of the changes in
cerebral activation studied with PET during working memory tests are task specific. PET
studies executed during Wisconsin Card sorting Test, which depends heavily on working
memory, has demonstrated reduction of activation with age in the dorsolateral prefrontal
cortex. On the other hand PET executed during Raven’s Progressive Matrices, which also has
a working memory component, but depends more on visuospatial processing, has demon‐
strated reduction of activation with age in in portions of the inferolateral temporal cortex more
involved in visuo-spatial processing (Esposito ed al., 1999).
Recent PET studies of brain activation during tasks of visuospatial processing have reported
that age-related cognitive changes are accompanied by altered cerebral activation in temporo-
occipital and extrastriate regions (Grady et al., 1994). Increased prefrontal activation was found
both during face and location processing (Grady et al., 1994) and during memory recall (Cabeza
et al., 1997a), while reduced prefrontal activation was reported during memory encoding
(Grady et al., 1995; Cabeza et al., 1997b).
Temporal resolution of hemodynamic techniques such as PET or fMRI can be improved
combining the activation maps from these imaging modalities with high-temporal resolution
information obtained by other sources such as EEG/MEG or information on tissue oxygenation
obtained from diffusion optical tomography. Recent methods of statistical combination of
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these techniques may provide benefits especially to neurosurgeon (Fischl et al., 2001; Dale et
al., 2000).
3. Pet study of cognitive functions in cerebrovascular disease
Cerebrovascular  disease affects  prominently elderly persons through alterations in brain
structure  and  metabolism  that  produce  cognitive  decline.  Cognitive  deficit  revealed  in
cerebrovascular disease regards especially the domains of executive functions (Starkstein
et al., 1996), attention, language (Powell et al., 1998) and less prominent memory deficits
(Villardita,  1993;  Tierney  et  al.,  2001).  Vascular  cognitive  disorders  may  be  caused  by
multiple  neuropathological  substrates,  including  multi-infarct  encephalopathy,  single
infarcts in strategic areas, lacunas and lacunar states, Biswanger’s leukoencephalopathy and
leukoarariosis, hippocampal sclerosis, watershed infarcts and neuronal loss/atrophy due to
diffuse hypoperfusion (Ferrer,  2010).  These substrates  can be a  consequence of  different
vascular diseases including atherosclerosis, small vessel disease, hypertensive angiopathy,
inflammatory  disease  of  blood  vessels,  inherited  vascular  disorders  such  as  amyloid
angiopathy  and  CADASIL  (central  autonomic  dominant  arteriopathy  with  subcortical
infarcts  and  leukoencephalopathy)  or  the  consequence  of  single  or  multiple  cerebral
hemorrhages.
Despite the considerable degree of accuracy in diagnosing Alzheimer’s disease (AD), the
clinical differentiation with Vascular cognitive impairment (cognitive impairment in absence
of dementia) and mixed dementia (Alzheimer’s disease plus cerebrovascular disease) remains
a matter of controversial opinions and one of the most challenging diagnostic issues (Misciagna
et al., 2005). Dementia in older adults is frequently caused by the combined conditions of
Alzheimer disease and cerebrovascular disease (mixed disease) since frequently occur together
in overlap presentations (such as vascular lesions in Alzheimer Disease or cerebral atrophic
condition in Cerebrovascular Disease). Nevertheless, there is evidence that they contribute
separately to the development of cognitive impairment and dementia (Snowdon et al., 1997;
Bennett, 2001).
The differential diagnosis between Alzheimer disease and dementia in cerebrovascular disease
known as Vascular Dementia (VaD) is based on presence of vascular risk factors (such as
hypertension, atrial fibrillation, obstructive arteriopathy, previous strokes or transitory
ischemic attacks), clinical features (such as acute onset, stepwise progression, emotional
lability) (Hachinski et al., 1974) and is supported by results of neuropsychological tests and
neuroimaging. Whereas computed tomography or magnetic resonance are able to detect
morphological lesions related to vascular disease, these modalities cannot determine func‐
tional impairment. PET allows imaging of the localized and/or diffuse metabolic disturbances
responsible for cognitive impairment and dementia and is effective in differentiating vascular
from degenerative dementia (Heiss and Zimmermann-Meinzingen, 2012). In particular PET
can differentiate areas of focal cortical and subcortical hypometabolism that differ from the
typical metabolic pattern seen in AD characterized by marked hypometabolism in association
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areas (Benson et al., 1983). In patients with severe Vascular Dementia, PET reveals a signifi‐
cative reduction of metabolism in widespread cerebral regions as middle frontal cortex,
temporoparietal cortex, basal ganglia, cerebellum and brainstem (Mielke et al., 1992). Hypo‐
metabolism is more marked than AD in subcortical areas and primary sensorimotor cortex,
while it is less affected in the association areas.
The metabolic ratio, which reflects the pattern of metabolic pathology in AD, is generally
higher in VaD than in AD. Both in VaD and AD there is a parallel decline of the metabolic ratio
with increasing dementia severity suggesting equal ability to discriminate VaD and AD in
early and advanced stages of the disease. The volume of functional loss detected with PET is
also important since it includes the effects of incompletely infarcted tissue and morphologically
intact but deafferented cortex. Diagnostic accuracy for classification of patients in VaD versus
AD is clearly superior for FDG PET even in patients with mild cognitive impairment (Mielke
et al., 1994).
In a study on 153 subjects PET differentiated VaD from AD demonstrating lower metabolism
in deep gray nucley, cerebellum, primary cortices, middle temporal gyrus and anterior
cingulate cortex in VaD, whereas in AD showed lower metabolism in hippocampal region,
orbitofrontal, posterior cingulate and posterior parietal cortices (Kerrouche et al., 2006).
PET can also detect vascular inflammatory changes (Mehta et al., 2012) and their interaction
with amyloid depositions for development of mixed dementias after stroke (Heiss & Zimmer‐
mann-Meinzingen, 2012). Microglia activation that occurs in patients with mild cognitive
deficits is not proven to be correlated with amyloid deposition as imaged by 11C-PIB (Okello
et al., 2009). However, in animal models, the inflammation due to an infarct is exacerbated in
the presence of amyloid; compared to animals without amyloid deposition the infarcts induced
in presence of amyloid grew over time (Whitehead et al., 2007). The interaction of inflammatory
reaction and amyloid deposition can be relevant for development of dementia in cerebrovas‐
cular disease as studied by multitracer PET with PK 11195 and PIB (Mok et al., 2010).
Episodic  memory  decline  and  hippocampal  cerebral  volume  (typically  associated  with
Alzhemier disease) are related to temporo-parietal hypometabolism (Desgranges, Chételat
and Eustache, 2004) while executive dysfunction and white matters hyperintensities (typical
of cerebrovascular disease) correlate with frontal lobe hypometabolism (Tullberg et al 2004).
On the bases of this hypothesis a fluorodeoxyglucose-PET longitudinal study on 38 subjects
ranging from normal condition to dementia in a follow up of 2 years have demonstrated
a different pattern of metabolic decline in condition of dementia in Alzheimer disease or
in cerebrovascular disease. In fact low baseline hippocampal volume can predict develop‐
ment of medial temporal hypometabolism; on the other hand white matter hyperintensi‐
ties can predict hypometabolism over time in the fronto-parietal regions (Kuczynski et al.,
2008). These studies suggest that pattern of cognitive decline studied with neuropsycholog‐
ical test batteries, anatomic changes and study of cerebral metabolism are useful in defining
etiology  of  dementia  in  cerebrovascular  disease  and  understand  future  evolution  of
cognitive deficits.
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4. Pet study of cognitive functions in normal ageing, mild cognitive
impairment and degenerative dementias
With normal aging neocortical neurons are lost in specific regions (Morrison, 1997), dendridic
trees undergo progressive regression and axons degenerate leading to an age-related axonal
loss. This process leads to a decrease of myelinated nerve fibers of 45% from the age of 20 to
80 years (Marner et al., 2003) and a reduction of the number of synapses by 15 to 50% (Pannese,
2011). The cerebral morphological changes that occur during normal ageing develop cognitive
changes in particular about memory that could be considered age-related and a physiological
process. These cognitive changes are related to physiological age-related brain atrophy with
concomitant ventricular enlargement (Rusinek et al., 2003) and to a diffuse and frontally
accentuated degrease of glucose metabolism as revealed with PET (Pawlik et al., 1989). The
condition of “age associated memory impairment” is characterized by self perception of
memory loss and standardised memory test score that shows low performances in memory
tasks compared with younger adults. By contrast, “mild cognitive impairment” (MCI) is
considered a transitional state between normal ageing and dementia (Petersen, 2004). Subjects
with MCI are indipendent in activity daily living even if suffer with cognitive deficits in
particular in the area of memory (in the amnestic form of MCI) typically in delayed recall,
althought non-memory cognitive domains might also be impaired (in non-amnestic form of
MCI). Patients with the amnestic subtype of MCI frequently progress to Alzheimer disease
(AD) (Petersen et al., 2006) so that MCI is associated with an increased risk of developing
dementia. When cognitive impairment concerns not only memory, but also other cognitive
domains (such as abstract reasoning, judgment capabilities, language, praxic, gnostic or spatial
function) dementia is often diagnosed (American Psychiatric Association, 2000). Alzheimer
Disease is the most common cause of progressive form dementia in which cognitive decline
interferes significantly with activities of daily living. Other causes of common degenerative
dementia include dementia with Lewy bodies (characterized by fluctuating consciousness,
parkinsonian symptoms and progressive decline in visuospatial, visuoperceptual, literacy and
praxic skills, including visual allucinations) and Frontotemporal dementia (characterized by
executive dysfunction, changes in personality and behaviour, semantic deficits and progres‐
sive aphasia). Secondary forms of dementia include depression (pseudo-depressive dementia),
drug toxic effects or other medical conditions.
Many of brain changes that occur in neurodegenerative disease can be evidenced by neuroi‐
maging technologies designed to identify alterations of cerebral biological processes. The main
brain change consists in focal or diffuse cerebral atrophy induced from neuronal synaptic
degeneration and loss of neurons. Some forms of dementia have a particular pattern of athophy
(Josephs et al., 2007). For example, widespread atrophy or medial temporal atrophy points
toward a pathologic diagnosis of Alzheimer Disease, fronto-temporal loss suggest a diagnosis
of Frontotemporal Dementia (Neary et al., 2005), more focal atrophy predominantly involving
the premotor and supplemental motor area suggests Corticobasal Degeneration (CBD) or
Progressive Supranuclear Palsy (PSP) (Whitwell et al., 2010); on the contrary Lewy bodies
disease is characterised by posterior cortical atrophy (Crutch et al., 2012). Other cerebral
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anomalies observed in auptoptical studies conducted in middle-aged adults (Price & Morris,
1999), patients with MCI (Petersen et al., 2006) or Alzheimer Disease (Braak & Braak, 1991)
consist in presence of plaques of amyloid ß and neurofibrillary tangles of tau protein.
Neurofibrillary tangles have been observed in the hippocampus and temporal regions in MCI,
in neocortical areas (frontal and parietal cortex) as MCI progress to AD. Patients with autoptical
diagnosis of Alzheimer disease have a hight number of both amyloid plaques and neurofi‐
brillary tangles (McKhann et al., 1984).
Cerebrospinal fluids (CSF) studies conducted on patients with AD (Sidoryk-Wegrzynowicz et
al., 2011) or post-mortem (Reinikainen et al., 1990) have documented alterations in cholinergic,
serotonergic, dopaminergic, somatostatinergic, noradrenergic and glutamatergic neurotrans‐
mitters. These and other pathogenetic mechanism as insulin resistance (Craft, 2006) contribute
to compromise cerebral regional glucose metabolism studied in PET techniques.
Studies conducted on patients with AD often use the radiolabelled glucose analogue FDG
([18]FDG-PET) to measure cerebral glucose metabolism, which indicates the levels of neuro‐
synaptic activity. PET studies have demonstrated that Alzheimer’s disease is characterized by
regional impairment of cerebral glucose metabolism in neocortical association areas (posterior
cingulate, temporoparietal and frontal multimodal association cortex), whereas the primary
visual and sensorimotor cortex, basal ganglia, and cerebellum are relatively well preserved
(for a review see Herholz, 2003).
An automated voxel-based analysis of FDG-PET images can distinct AD from controls with
93% sensitivity and 93% specificity as dimonstrated in a multicentre study comprising 10 PET
centers (Herholz et al., 2002).
These studies have shown that cortical brain alterations begin in the posterior cingulate regions
and spread to the temporal and prefrontal cortices. This pattern of brain metabolism is useful
to differentiate patients with AD from other forms of dementia and from cognetively health
people (Silverman et al., 2001).
Regional cortical hypometabolism also correlates with greater cognitive losses so that [18]FDG-
PET can differentiate patients with MCI from others with AD or normal subjects (Small et al.,
2006).
When [18]FDG-PET is added to standard clinical assessment, diagnostic accuracy for dementia
of Alzheimer type increases sensitivity and specificity (Jagust et al., 2007). [18]FDG-PET is
important in helping differential diagnosis between AD and Frontotemporal Dementia since
the latter dementia do not seem to respond well to currently available symptomatic treatments.
Longitudinal studies of patients with MCI have found that if baseline assessment with
[18]FDG-PET scan suggests an AD-like pattern, the probability of conversion in AD within
several years is extremely hight (Drzezga et al., 2005; Chételat et al., 2003). Therefore in these
MCI patients pharmacological treatment with specific anti-dementia drugs could be achieved,
so that might be modified the trend of the desease and reduce social costs of illness.
[18]FDG-PET assists the diagnosis of AD when combined with specific genetic assessment. In
fact hypomethabolism in posterior cingulate, parietal, prefrontal, entorhinal and temporal
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regions have been found to predict future cognitive decline in older APOE ε4 carriers than
non-carriers (Small et al., 2000). Moreover several [18]FDG-PET studies have shown that
patients with MCI and AD-like metabolic pattern are hightly predictive of conversion to AD
within several years, in particular in patiens that are APOE ε4 carriers (Mosconi et al., 2004).
[18]FDG-PET scans, when combined with Magnetic Resonance imaging and other biomarkers,
are likely to improve diagnostic accuracy (Mueller et al., 2005) and might be used to monitor
treatment that affect cerebral blood flow, metabolism, or neuronal dysfunction.
Characteristic patterns of regional hypometabolism are also seen in other degenerative
dementia (Bohnen et al., 2012). Frontotemporal dementia is identified by distinct frontal or
frontotemporal metabolic impairment that are typically quite asymmetrically centered in the
frontolateral cortex and the anterior pole of temporal lobe. Dementia with Lewy bodies shows
reduction of glucose metabolism in primary visual cortex in addition to that in posterior
association areas. Other degenerative disorders show typical hypomethabolism in the
specifically affected brain structures: the putamen and cortex in corticobasal degeneration, the
caudate nucleus in Huntington’s chorea, the frontal cortex and midbrain in progressive
supranuclear palsy, pons and cerebellum in olivopontocerebellar atrophy.
In recent years different small molecule probes have been developed for use with PET to
measure deposits of amyloid- ß plaques and tau tangles in vivo (Klunk et al., 2004; Kudo et
al., 2007). The most studied amyloid-binding radiotracer is [11C]PIB ([11C]-labelled Pittsburg
Compound B) which is a derivative of thioflavin-T amyloid dye that binds specifically
amyloid-ß plaques but not neurofibrillary tangles. Studies using [11C]PIB-PET have demon‐
strated cortical retention in patients with AD compared with normal subjects (Klunk et al.,
2004). Studies of MCI patients have showed that [11C]PIB uptake is increased in approximately
50% of them (Kemppainen et al., 2007). [11C]PIB-PET could potentially be used to diagnose
cerebral amyloid angiopathy since it also detects cerebrovascular amyloid (Johnson et al.,
2007). PET studies with [11C]PIB is useful in differential diagnosis of degenerative type of
dementia, since patients with Lewy bodies dementia show lower binding than in AD, while
patients affected with Fronto-temporal dementia show no cortical binding (Rowe et al., 2007).
Recently several 18F labelled amyloid tracers are commercially available permitting large scale
clinical use (Rowe and Villemagne, 2011).
[18F]-BAY94-9172-PET, based on amyloid legand florine-18, could be used to discriminate
patients with AD from frontotemporal dementia and healthy controls (Rowe et al., 2008).
Tau deposition in neurofibrillary tangles together with amyloid can be specifically detect by
the tracer [18F]-FDDNP, providing additional insight in AD pathology (Small et al., 2008).
Other PET legands have been used in research to measure functionality of many neurotrans‐
mitter systems such as serotoninergic, cholinerdic and dopaminergic. The neurotrasmitters
systems are impaired in various types of dementia and may help in differential diagnosis and
in the definition of pathophysiological process. MPPF (4-[18F]-fluoro-N-piperazynil-N-2-
methoxy-phenyl-pyridinil benzamide) is a molecular imaging probe for 5-HT1A receptorswhich density correlates with the number of pyramidal neurons of the hippocampus (Kepe et
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al., 2006). Patients with AD show diminished hippocampal signal, while patients with MCI
show binding values intermediate between controls and Alzheimer’s disease patients (Kepe
et al., 2006). Since MPPF binding correlates with neuronal losses in the hippocampus, therefore
it can be used as an early diagnostic measure in the continuum between MCI and dementia
conversion, before onset of symptoms of dementia. PET radioligands used to visualize
cholinergic nicotinic receptors correlate with cognitive measure of attention in Alzheimer’s
disease (Kadir et al., 2006). PET measures of cholinergic system with 11C-nicotine can be used
to assess nicotine binding sites in the brain before and after treatment with anti-cholinesterase
drugs (Kadir et al., 2007).
[11C]ß-CFT ([11C]2ß-carbomethoxy-3ß-4fluorophenyl tropane) is a molecular dopamine
reuptake ligand used to study the cerebral dopaminergic system. Striatal uptake of [11C]ß-CFT
is reduced in patients with AD (Rinne et al., 1998). The ligand [11C]-PK11195 has been used in
other PET research to measure microglial activation as response to neuronal degeneration in
patients with Alzheimer Disease (Cagnin et al., 2001). Microglial activation seems to be an
inflammatory reaction to amyloid deposition that might increase the formation of pathological
protein deposits.
5. Conclusions
An enormous progress has been made in the science of human cognition using neuroimaging
and integration with neuropsychological assessment, multimodal structural and functional
imaging technologies based on study of cerebral glucose metabolism as in Positron Emission
Tomography. PET exam has led to a revolution in understanding of the basic neuroscience
principles involved in where and how the brain processes information both in normal subjects
and in patients with cerebral lesions.
Different PET methodologies in combination with traditional neuroimaging techniques are
more and more used to accurately localize and characterize cognition not invasively.
The current clinical applications of using PET or other functional neuroimaging to mapping
cognitive function include lateralization and presurgical mapping of language and memory
mapping (Stufflebeam and Rosen, 2007). The development of advanced techniques and the
combination of imaging technologies is further expanding the understanding of cognitive
processing and is extending the clinical applications of functional neuroimaging into new
areas.
With recent advances in neuroimaging technology novel PET applications are developing to
measure various biological processes or to study cognitive alterations in patients with diseases
that affect central nervous system. Combining PET procedures with other neuroimaging
studies, genetic risk measures and other biomarkers measures from other tissues it might
increase diagnostic sensitivity and specificity in particular in differential diagnosis of demen‐
tia, in the early stages of vascular or degenerative dementia, since presence of different PET
pattern (neocortical association areas in AD, frontolateral cortex and anterior pole of temporal
lobe in FTD, posterior association areas in LBD).
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PET investigations will increase understanding and monitor pathophysiological process of
many neurological diseases, track the biological effects of treatments in clinical trials and assist
in identifying responders to specific treatments (Reiman et al., 2001). Several of the neuroi‐
maging technologies in development promise in proving measurement of potential biomark‐
ers but further research is necessary to validate their use. In fact many of these methods are
still used in research settings and require further studies to better understand their clinical
usefulness. Another limitation to the adoption of PET techniques is the relatively high cost and
lack of wide availability, but when compared costs to the high diagnostic accuracy of PET,
these benefits incurred high costs (McMahon et al., 2003). In future, with more extensive use
of these new PET technology, costs will also decline and improvement of diagnostic accuracy
will lead to cost saving. For example healthy adults with risk factors for cognitive decline (e.g.
age, previous head trauma, familiar history) might undergo a PET check scan for measures of
cognitive decline risk and physicians will use medications or other interventions to prevent or
delay onset of disease or avoid future cognitive losses.
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